论文部分内容阅读
目的对急性脑梗死应用法舒地尔治疗前后血CRP、FIB水平的变化及意义进行探讨分析。方法回顾性分析我院于2012年4月-2014年10月收治的200例急性脑梗死患者的病历资料,随机的分为对照组和治疗组,对照组和治疗组各100例,对照组中的100例患者采取常规治疗,治疗组患者在常规治疗的基础上应用法舒地尔治疗,对比分析两组患者的治疗效果,并对两组患者治疗前、治疗中以及治疗后CRP、FIB水平的变化进行分析。结果对照组急性脑梗死患者应用法舒地尔治疗总有效率(98%)明显高于对照组临床治疗效果(78%),P<0.05,有统计学意义。急性脑梗死患者治疗之前对照组和治疗组患者的血清C反应蛋白和血浆纤维蛋白原水平进行比较,P>0.05,无统计学意义,有可比性。急性脑梗死患者应用法舒地尔治疗之后患者的血清C反应蛋白和血浆纤维蛋白原水平逐渐得到改善,同时其改善效果明显优于对照组,P<0.05,有统计学意义。治疗组患者经法舒地尔治疗有着较好的耐受性,同时对于患者的血压、心率以及呼吸等生命体征没有负面影响,治疗组和对照组患者治疗前中后TESS评分进行比较,P>0.05,无统计学意义,有可比性。结论急性脑梗死患者应用法舒地尔治疗,有着较好的临床疗效,同时还可将患者的血清C反应蛋白和血浆纤维蛋白原水平降低,并对患者的症状有着改善作用,有着极高的临床应用价值,值得临床推广。
Objective To investigate the changes of blood levels of CRP and FIB in patients with acute cerebral infarction before and after fasudil treatment. Methods The clinical data of 200 acute cerebral infarction patients in our hospital from April 2012 to October 2014 were retrospectively analyzed. They were randomly divided into the control group and the treatment group, the control group and the treatment group, each with 100 cases in the control group Of 100 patients taking conventional treatment, the treatment group patients on the basis of routine treatment with fasudil treatment, comparative analysis of the two groups of patients with treatment, and two groups of patients before treatment, after treatment and after treatment CRP, FIB levels The changes were analyzed. Results The total effective rate (98%) of fasudil in patients with acute cerebral infarction was significantly higher than that of the control group (78%), P <0.05, which was statistically significant. The levels of serum C-reactive protein and plasma fibrinogen in patients with acute cerebral infarction before treatment were compared in the control group and the treatment group, P> 0.05, without statistical significance and comparability. Serum C-reactive protein and plasma fibrinogen levels were gradually improved in patients with acute cerebral infarction after fasudil treatment, and the improvement was significantly better than the control group, P <0.05, statistically significant. The patients in the treatment group had better tolerance to fasudil treatment and no negative effects on the blood pressure, heart rate and vital signs such as respiration. The TESS scores of the treatment group and the control group before and after treatment were compared, P> 0.05, no statistical significance, comparable. Conclusion Fasudil treatment in patients with acute cerebral infarction has a good clinical efficacy, while patients with serum C-reactive protein and plasma fibrinogen levels decreased, and the patient’s symptoms have improved, with a very high Clinical application value, it is worth clinical promotion.